Thirteen percent of Americans—about 38 million people—suffer from migraine, and every one of them has a different experience with the condition. Treatment has to be as individualized as they are.

This ‘woman’s disease’ doesn’t get a lot of research funding, but the medical establishment has made strides in developing new drugs and devices to combat migraine over the last five years. By Melinda ...

The treatment is administered subcutaneously into the skin of the middle thigh. The Food and Drug Administration (FDA) has approved Brekiya ® (dihydroergotamine mesylate) injection for the acute ...

New guidelines recommend a sequential treatment approach for episodic migraine, starting with beta-blockers, antiseizure medications, SNRIs, and TCAs. CGRP antagonists and monoclonal antibodies are ...

Laurie Knepper, MD, is an associate professor of neurology at the University of Pittsburgh School of Medicine The information here represents her research and knowledge as a medical professional.

Selecting a treatment plan to deal with acute migraine attacks can be like putting together a toolkit of possible therapies, individualized for each patient, one expert said. The toolkit should ...

“The process of getting an accurate migraine diagnosis was one of the most confusing, fearful, and difficult periods of my life,” Natalie Sayre tells SELF. Sayre, 28, lived with chronic migraine for ...

Credit: Axsome Therapeutics Symbravo is expected to be available in approximately 4 months. Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug ...

Migraine is a disabling neurological disorder, triggered by stress, changes in sleep and weather, and other things. It can cause unbearable pain that lasts hours or even days. Migraine and other ...

Migraine sufferers across the United States have their eyes on a newly approved drug that’s offering hope for reducing the frequency of monthly migraine attacks. On Thursday, the US Food and Drug ...